Scilex Holding (SCLXW) Interest Expenses (2021 - 2026)
Scilex Holding (SCLXW) recorded quarterly Interest Expenses of $3.8 million in Q1 2026, up 8.03% quarter-over-quarter from $3.5 million in Q4 2025, and up 52.32% on a YoY basis from $2.5 million in Q1 2025.
Scilex Holding (SCLXW) Interest Expenses (2021 - 2026) Analysis & Trends
Scilex Holding's Interest Expenses history runs 6 years deep, the most recent figure standing at $3.8 million for Q1 2026.
- In Q1 2026, Interest Expenses rose 52.32% year-over-year to $3.8 million; the TTM figure through Mar 2026 stood at $12.8 million (up 226.02% YoY), while the FY2025 annual figure was $11.5 million, up 483.75% from the prior year.
- Interest Expenses was $3.8 million for Q1 2026 at Scilex Holding, up from $3.5 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $5.3 million in Q1 2023 to a low of $7466.0 in Q1 2022.
- Historically, Interest Expenses has averaged $1.8 million across 5 years, with a median of $1.0 million in 2022.
- The sharpest annual moves came in 2023 and 2024: Interest Expenses jumped 70513.45% in 2023, then plunged 89.93% in 2024.
- A 5-year view of Interest Expenses shows it stood at $1.0 million in 2022, then plunged by 45.34% to $551000.0 in 2023, then sank by 48.28% to $285000.0 in 2024, then soared by 1127.37% to $3.5 million in 2025, then climbed by 8.03% to $3.8 million in 2026.
- The last three Interest Expenses figures came in at $3.8 million (Q1 2026), $3.5 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -225.15 Mn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 272.00 Mn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | - |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 657.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 240.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | - |
| 10 | Scilex Holding | - | - | 4.15 Mn | 3.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.78 Mn |
| Mar 31, 2026 | 3.78 Mn |
| Dec 31, 2025 | 3.50 Mn |
| Dec 31, 2025 | 3.50 Mn |
| Sep 30, 2025 | 2.80 Mn |
| Sep 30, 2025 | 2.80 Mn |
| Jun 30, 2025 | 2.68 Mn |
| Jun 30, 2025 | 2.68 Mn |
| Mar 31, 2025 | 2.48 Mn |
| Mar 31, 2025 | 2.48 Mn |
| Dec 31, 2024 | 285,000.00 |
| Dec 31, 2024 | 285,000.00 |
| Sep 30, 2024 | 576,000.00 |
| Sep 30, 2024 | 576,000.00 |
| Jun 30, 2024 | 571,000.00 |
| Jun 30, 2024 | 571,000.00 |
| Mar 31, 2024 | 531,000.00 |
| Mar 31, 2024 | 531,000.00 |
| Dec 31, 2023 | 551,000.00 |
| Dec 31, 2023 | 551,000.00 |